CUV - Clinuvel Pharmaceuticals

[Dona Ferentes]

Congrats to any holders, nice X'mas present that has arrived early
DNH.

That was as much lasting use as most Xmas presents (buy on rumour, sell on fact?!)

 

[Pugt16]

That was as much lasting use as most Xmas presents (buy on rumour, sell on fact?!)

I guess some would see it like that.
And I wonder how they'll see it when it's at $100.

 

[xris]

CUV: is One of my picks for the 2022 tipping Comp.
Perhaps the first Biomed company to synthesise and patent a bio-effective molecule

 

[Dona Ferentes]

 

[frugal.rock]

4 cent divvy. Piddlers.
Punters like the results I guess.

 

[mullokintyre]

CUV back in the News.
From The Australian

ASX-listed biotech Clinuvel is planning to expand beyond rare diseases to prevent one of the most common cancers, tapping into a multibillion-dollar market.
Clinuvel has completed a successful trial on its drug afamelanotide, with the study showing it reduced damage from UV radiation in people with fair skin.

UV radiation damage is a leading factor in skin cancer – which costs $US8.1bn ($11.3bn) to treat each year in the US alone – and photoaging, premature skin ageing from prolonged and repeated exposure to solar radiation. The study showed that afamelanotide could significantly reduce artificially provoked sunburn damage after six days, indicating its potential use in preventing skin cancer development.

The trial, completed in the UK, comes after Clinuvel successfully completed a phase two study aimed at protecting patients with xeroderma pigmentosum – a rare genetic disorder that put those with the condition at greater risk of developing aggressive skin cancers.

Wilsons analyst Melissa Benson said the positive results from the latest trial were “not earth shattering or unexpected” but “continues to speak to the potential for broader applications” of afamelanotide than treating rare disease.

“Melanoma represents a common cancer type, with a high mortality rate, despite treatment advances,” Dr Benson said

“Novel therapies to reduce melanoma incidence presents a material opportunity, down the line.

“(About) 100,000 new melanoma cases are diagnosed in the US each year, with 8000 deaths owing to melanoma. Australia carries one of the highest burdens of melanoma globally.”

Local biotech companies are back on the world stage, with the biggest Australian delegation since the Covid-19 pandemic descending on JP Morgan’s major health conference in San Francisco last month – setting up for a year of deal making.

Clinuvel shares advanced 1.8 per cent to $24.56 in afternoon trade on Thursday, giving the company a market value of $1.2bn.

This stock seems to go in cycles, was above 45 when it was a market darling.
Perhaps this will spark the love.
Mick

 

[arco]

I've been looking at CUV for a possible opportunity,
(Bought previously In June 21 @ 24.25 and sold)

Weekly chart showing resistance 28.95
Looking to me like there will be a retrace back now to around Kumo base before moving on.
Might dip my toes in at c $20 if it gets there.

 

[Dona Ferentes]

this one used to be a darling to some true believers on now-extinct chat rooms in days of yore.

it's still around; some commentary, below, leaves me underwhelmed and bemused in equal measure.

Clinuvel CEO returns, but acting CEO remains until September

Clinuvel Pharmaceuticals (ASX:CUV) announced on 13 June 2025 that Dr Philippe Wolgen has returned to the company full time as Managing Director following medical leave. However, Lachlan Hay will continue as Acting CEO until the end of September 2025. Dr Wolgen will focus on key product development and corporate initiatives during this transition period. The update suggests a staggered handover rather than an immediate return to full executive leadership, contributing to ongoing investor uncertainty amid a broader context of share price pressure and strategic repositioning.

.
reposition that ^^